

# Michiel Coppens

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/905373/publications.pdf>

Version: 2024-02-01

59  
papers

3,562  
citations

448610

19  
h-index

156644

58  
g-index

62  
all docs

62  
docs citations

62  
times ranked

6397  
citing authors

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 1  | Estimating Bleeding Risk in Patients with Cancer-Associated Thrombosis: Evaluation of Existing Risk Scores and Development of a New Risk Score. <i>Thrombosis and Haemostasis</i> , 2022, 122, 818-829.         | 1.8 | 23        |
| 2  | Lipoprotein(a), venous thromboembolism and COVID-19: A pilot study. <i>Atherosclerosis</i> , 2022, 341, 43-49.  | 0.4 | 28        |
| 3  | Risk of recurrence in women with venous thromboembolism related to estrogen-containing contraceptives: Systematic review and meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 1158-1165. | 1.9 | 11        |
| 4  | Design of a Prospective Study on Pharmacokinetic-Guided Dosing of Prophylactic Factor Replacement in Hemophilia A and B (OPTI-CLOT TARGET Study). <i>TH Open</i> , 2022, 06, e60-e69.                           | 0.7 | 1         |
| 5  | Effect of polypharmacy on bleeding with rivaroxaban versus vitamin K antagonist for treatment of venous thromboembolism. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 1376-1384.                    | 1.9 | 7         |
| 6  | Joint status of patients with nonsevere hemophilia A. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 1126-1137.   | 1.9 | 17        |
| 7  | Gene therapy of hemophilia: Hub centres should be haemophilia centres: A joint publication of EAHAD and EHC. <i>Haemophilia</i> , 2022, 28, .   | 1.0 | 10        |
| 8  | The bleeding phenotype in people with nonsevere hemophilia. <i>Blood Advances</i> , 2022, 6, 4256-4265.   | 2.5 | 10        |
| 9  | Effect of polypharmacy on bleeding with rivaroxaban versus vitamin K antagonist for treatment of venous thromboembolism Reply. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 1748-1749.              | 1.9 | 0         |
| 10 | Postthrombotic syndrome and quality of life after deep vein thrombosis in patients treated with edoxaban versus warfarin. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12748.         | 1.0 | 2         |
| 11 | Treatment of acquired hemophilia A, a balancing act: results from a 27-year Dutch cohort study. <i>American Journal of Hematology</i> , 2021, 96, 51-59.  | 2.0 | 21        |
| 12 | Mortality, life expectancy, and causes of death of persons with hemophilia in the Netherlands 2001-2018. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 645-653.                                      | 1.9 | 48        |
| 13 | Similar sports participation as the general population in Dutch persons with haemophilia; results from a nationwide study. <i>Haemophilia</i> , 2021, 27, 876-885.  | 1.0 | 14        |
| 14 | Perioperative pharmacokinetic-guided factor VIII concentrate dosing in haemophilia (OPTI-CLOT trial): an open-label, multicentre, randomised, controlled trial. <i>Lancet Haematology</i> , 2021, 8, e492-e502. | 2.2 | 9         |
| 15 | Treatment-related risk factors for inhibitor development in nonsevere hemophilia A after 50 cumulative exposure days: A case-control study. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2171-2181. | 1.9 | 8         |
| 16 | Health and treatment outcomes of patients with hemophilia in the Netherlands, 1972-2019. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2394-2406.  | 1.9 | 21        |
| 17 | Incidence and mortality rates of intracranial hemorrhage in hemophilia: a systematic review and meta-analysis. <i>Blood</i> , 2021, 138, 2853-2873.   | 0.6 | 23        |
| 18 | Validation of PROMIS Profile-29 in adults with hemophilia in the Netherlands. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2687-2701.   | 1.9 | 16        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 19 | Delivery of AAV-based gene therapy through haemophilia centres – A need for re-evaluation of infrastructure and comprehensive care: A Joint publication of EAHAD and EHC. <i>Haemophilia</i> , 2021, 27, 967-973.   | 1.0 | 29        |
| 20 | First-in-Human Dose-Finding Study of AAVhu37 Vector-Based Gene Therapy: BAY 2599023 Has Stable and Sustained Expression of FVIII over 2 Years. <i>Blood</i> , 2021, 138, 3971-3971.   | 0.6 | 5         |
| 21 | Generic PROMIS item banks in adults with hemophilia for patient-reported outcome assessment: Feasibility, measurement properties, and relevance. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12621.  | 1.0 | 8         |
| 22 | Patient Perspectives on Novel Treatments in Haemophilia: A Qualitative Study. <i>Patient</i> , 2020, 13, 201-210.   | 1.1 | 28        |
| 23 | ETNA VTE Europe: A contemporary snapshot of patients treated with edoxaban in clinical practice across eight European countries. <i>European Journal of Internal Medicine</i> , 2020, 82, 48-55.  | 1.0 | 5         |
| 24 | ETNA-VTE Europe: Benefits and risks of venous thromboembolism treatment using edoxaban in the first 3 months. <i>Thrombosis Research</i> , 2020, 196, 297-304.  | 0.8 | 5         |
| 25 | Outcome of intracranial bleeding managed with prothrombin complex concentrate in patients on direct factor Xa inhibitors or vitamin K antagonists. <i>Thrombosis Research</i> , 2020, 196, 404-409.   | 0.8 | 0         |
| 26 | Predictors of preprocedural direct oral anticoagulant levels in patients having an elective surgery or procedure. <i>Blood Advances</i> , 2020, 4, 3520-3527.   | 2.5 | 38        |
| 27 | Illness cognitions associated with health-related quality of life in young adult men with haemophilia. <i>Haemophilia</i> , 2020, 26, 793-799.  | 1.0 | 2         |
| 28 | Optimal trough levels in haemophilia B: Raising expectations. <i>Haemophilia</i> , 2020, 26, e334-e336.   | 1.0 | 6         |
| 29 | Intracranial hemorrhage with direct oral anticoagulants in patients with brain metastases. <i>Blood Advances</i> , 2020, 4, 6291-6297.  | 2.5 | 28        |
| 30 | Incidence of venous thromboembolism in hospitalized patients with COVID-19. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1995-2002.   | 1.9 | 1,227     |
| 31 | Bleeding phenotype and diagnostic characterization of patients with congenital platelet defects. <i>American Journal of Hematology</i> , 2020, 95, 1142-1147.   | 2.0 | 9         |
| 32 | AMT-060 Gene Therapy in Adults with Severe or Moderate-Severe Hemophilia B Confirm Stable FIX Expression and Durable Reductions in Bleeding and Factor IX Consumption for up to 5 Years. <i>Blood</i> , 2020, 136, 26-26.   | 0.6 | 13        |
| 33 | First Data from the Phase 3 HOPE-B Gene Therapy Trial: Efficacy and Safety of Etranacogene Dezaparvovec (AAV5-Padua hFIX variant; AMT-061) in Adults with Severe or Moderate-Severe Hemophilia B Treated Irrespective of Pre-Existing Anti-Capsid Neutralizing Antibodies. <i>Blood</i> , 2020, 136, LBA-6-LBA-6. | 0.6 | 11        |
| 34 | Perioperative Management of Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant. <i>JAMA Internal Medicine</i> , 2019, 179, 1469.   | 2.6 | 283       |
| 35 | Desmopressin treatment combined with clotting factor VIII concentrates in patients with non-severe haemophilia A: protocol for a multicentre single-armed trial, the DAVID study. <i>BMJ Open</i> , 2019, 9, e022719.   | 0.8 | 7         |
| 36 | Professional functioning of young adults with congenital coagulation disorders in the Netherlands. <i>Haemophilia</i> , 2019, 25, e138-e145.  | 1.0 | 4         |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 37 | Stable FIX Expression and Durable Reductions in Bleeding and Factor IX Consumption for up to 4 Years Following AMT-060 Gene Therapy in Adults with Severe or Moderate-Severe Hemophilia B. <i>Blood</i> , 2019, 134, 2059-2059.                 | 0.6 | 42        |
| 38 | Effects of Andexanet Alfa on Thrombin Generation in Bleeding Associated with Factor Xa Inhibitors. <i>Blood</i> , 2019, 134, 711-711.   | 0.6 | 1         |
| 39 | Design and rationale of the non-interventional, edoxaban treatment in routine clinical practice in patients with venous ThromboEmbolism in Europe (ETNA-VTE-Europe) study. <i>Thrombosis Journal</i> , 2018, 16, 9.                             | 0.9 | 15        |
| 40 | Gene therapy with adeno-associated virus vector 5â€“human factor IX in adults with hemophilia B. <i>Blood</i> , 2018, 131, 1022-1031.   | 0.6 | 236       |
| 41 | Comparative effectiveness of transitional care services in patients discharged from the hospital with heart failure: a systematic review and network meta-analysis. <i>European Journal of Heart Failure</i> , 2017, 19, 1427-1443.             | 2.9 | 236       |
| 42 | Benefits and harms of 4-factor prothrombin complex concentrate for reversal of vitamin K antagonist associated bleeding: a systematic review and meta-analysis. <i>Journal of Thrombosis and Thrombolysis</i> , 2017, 44, 118-129.              | 1.0 | 47        |
| 43 | Coagulation factor XIII-A subunit and activation peptide levels in individuals with established symptomatic acute deep vein thrombosis. <i>Thrombosis Research</i> , 2017, 159, 96-99.  | 0.8 | 11        |
| 44 | Pharmacokinetics of dabigatran etexilate and rivaroxaban in patients with short bowel syndrome requiring parenteral nutrition: The PDER PAN study. <i>Thrombosis Research</i> , 2017, 160, 76-82.   | 0.8 | 13        |
| 45 | Recognition and Management of Hemostatic Disorders in Critically Ill Patients Needing to Undergo an Invasive Procedure. <i>Transfusion Medicine Reviews</i> , 2017, 31, 223-229.  | 0.9 | 7         |
| 46 | Safety of prothrombin complex concentrate in healthy subjects. <i>British Journal of Haematology</i> , 2017, 176, 664-666.  | 1.2 | 3         |
| 47 | The Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study for Patients on a Direct Oral Anticoagulant Who Need an Elective Surgery or Procedure: Design and Rationale. <i>Thrombosis and Haemostasis</i> , 2017, 117, 2415-2424. | 1.8 | 62        |
| 48 | Anticoagulants for the prevention and treatment of catheter-related thrombosis in adults and children on parenteral nutrition: a systematic review and critical appraisal. <i>Blood Transfusion</i> , 2017, 15, 369-377.                        | 0.3 | 13        |
| 49 | <i>In vivo</i> reversal of the anticoagulant effect of rivaroxaban with four-factor prothrombin complex concentrate. <i>British Journal of Haematology</i> , 2016, 172, 255-261.  | 1.2 | 48        |
| 50 | Primary thromboprophylaxis for adult patients on home parenteral nutrition: A comment on the 2016 ESPEN guideline. <i>Clinical Nutrition</i> , 2016, 35, 1579-1580.   | 2.3 | 5         |
| 51 | Interim Results from a Dose Escalating Study of AMT-060 (AAV5-hFIX) Gene Transfer in Adult Patients with Severe Hemophilia B. <i>Blood</i> , 2016, 128, 2314-2314.  | 0.6 | 5         |
| 52 | Effects of a hospital-wide introduction of a massive transfusion protocol on blood product ratio and blood product waste. <i>Journal of Emergencies, Trauma and Shock</i> , 2015, 8, 199.   | 0.3 | 18        |
| 53 | Recent Advances in Antidotes for Direct Oral Anticoagulants: Their Arrival Is Imminent. <i>Canadian Journal of Cardiology</i> , 2014, 30, 381-384.  | 0.8 | 20        |
| 54 | Sex, thrombosis and inherited thrombophilia. <i>Blood Reviews</i> , 2014, 28, 123-133.  | 2.8 | 56        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 55 | Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. <i>Blood</i> , 2014, 124, 1968-1975.  | 0.6 | 662       |
| 56 | Inherited Thrombophilias. <i>Obstetrics and Gynecology Clinics of North America</i> , 2006, 33, 357-374.   | 0.7 | 9         |
| 57 | A prospective cohort study on the absolute incidence of venous thromboembolism and arterial cardiovascular disease in asymptomatic carriers of the prothrombin 20210A mutation. <i>Blood</i> , 2006, 108, 2604-2607. | 0.6 | 65        |
| 58 | Natural Course of the Subsequent Pregnancy after a Single Loss in Women with and without the Factor V Leiden or Prothrombin 20210A Mutations.. <i>Blood</i> , 2006, 108, 275-275.                                    | 0.6 | 7         |
| 59 | Current Practice of Testing for Hereditary Thrombophilia in the Netherlands.. <i>Blood</i> , 2006, 108, 3288-3288.   | 0.6 | 0         |